Table 1.
Predicted anti-SARS-CoV-2 compounds in vitro efficacy testing from two independent rounds of testing.
| Compound | IC50 (μM) | CC50 (μM) | SI index | |
|---|---|---|---|---|
| Round 1 | Homoharringtonine | 0.16 | 2.14 | 12.84 |
| Bortezomib | 1.39 | > 50 | 35.93 | |
| Trametinib | 14.95 | > 50 | 3.34 | |
| Lacidipine | 14.89 | 20.15 | 1.35 | |
| Dasatinib | 19.74 | 13.20 | 0.67 | |
| Remdesivir | 12.08 | > 50 | 4.14 | |
| Chloroquine | 12.0 | 127.8 | 10.65 | |
| Round 2 | Ganetespib | 35.50 | 28.95 | 0.82 |
| Ixazomib | 11.71 | > 50 | 4.27 | |
| Tanespimycin | 31.33 | > 50 | 1.60 | |
| Bortezomib | 3.42 | > 50 | 14.63 | |
| Homoharringtonine | 0.26 | 6.22 | 24.06 | |
| Chloroquine | 9.80 | > 150 | 15.31 | |
| Remdesivir | 7.45 | > 50 | 6.71 | |
| Lopinavir | 13.50 | > 50 | 3.70 |
IC50, CC50, and SI index were calculated of each compound in SARS-CoV-2 infected in Vero cells. Homoharringtonine and bortezomib exhibited strong antiviral activities with corresponding cytotoxicity CC50 at least 20 times higher than the viral killing IC50.